Tag Archives: Progression of Mild Cognitive Impairment to Dementia

Exploring Lived Space as Experienced by Persons With Dementia (BMC Geriatrics)

Posted on July 16, 2018 by Dementia and Elderly Care News

Summary A systematic meta-synthesis concerning the broad topic of the experience(s) of space (whether physical, social or existential) on the part of persons living with dementia has identified four domains in the experience of “lived space”: (i) belonging (ii) meaningfulness … Continue reading →

Brain Training Game May Improve Symptoms of Amnestic Mild Cognitive Impairment? (NHS Choices / International Journal of Neuropsychopharmacology)

Posted on July 11, 2017 by Dementia and Elderly Care News

Summary A small research study, involving older persons with mild cognitive impairment (MCI), indicates that cognitive training delivered in the form of a brain training game (the app called “Game Show”) may help improve memory and might potentially reduce / … Continue reading →

Posted in For Researchers (mostly), In the News, International, Management of Condition, NHS Digital (Previously NHS Choices), Non-Pharmacological Treatments, Person-Centred Care, Quick Insights, UK, Universal Interest | Tagged Active Engagement, Amnestic Mild Cognitive Impairment (a-MCI), Amnestic Mild Cognitive Impairment (aMCI), Apathy Evaluation Scale (AES), Behind the Headlines, Brain Training, Brain Training Games, Brief Visuospatial Memory Test-Revised (BVMT-R), Cambridge and Peterborough NHS Foundation Trust, Cambridge Neuropsychological Test Automated Battery Paired Associates Learning (PAL), Cambridge University Hospitals NHS Foundation Trust, CANTAB Choice Reaction Time (CRT), CANTAB Paired Associates Learning, Cognitive Training, Cognitive Training Exercises, Computer Games, Computerised Touch Screen Games, Critical Appraisals, Dementias and Neurodegeneration NIHR Clinical Research Network (Eastern DeNDRon), Department of Clinical Neurosciences and MRC Cognition and Brain Sciences Unit: University of Cambridge, Department of Psychiatry: University of Cambridge, Department of Psychological Sciences: University of East Anglia, Effects of Cognitive Training on General Cognition and Neuropsychiatric Symptoms, Enjoyment and General Engagement, Episodic Memory, Eton College, Game Show app, Game Show Cognitive Training app, Gamification, Gamification (Improved Engagement and Motivation), Gamified Cognitive Training, Geriatric Depression Scale (GDS Short Form), Hospital Anxiety and Depression Scale (HADS), Information Technology, International Journal of Neuropsychopharmacology, Intrinsic Motivation, Involvement and Participation, Ipad Technology, Janssen Pharmaceutical, Johnson and Johnson, Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), Mini Mental State Examination (MMSE), Motivational Enhancement, MRC / Wellcome Trust Behavioural and Clinical Neuroscience Institute, Neuropsychological Assessment, New Technology, Norfolk and Suffolk NHS Foundation Trust, Paired Associates Learning, Positive Engagement, Progression of Mild Cognitive Impairment to Dementia, Rates of Conversion From Mild Cognitive Impairment to Dementia, University of Cambridge, University of East Anglia, Wallitt Foundation, Wellcome Trust, Wellcome Trust Behavioural and Clinical Neuroscience Institute: University of Cambridge | Leave a comment

BBC iWonder Guide: How Close Are We to Stopping Alzheimer’s Disease? (BBC News)

Posted on November 27, 2016 by Dementia and Elderly Care News

Summary The BBC’s iWonder Guides provide “thought-provoking answers to the questions sparked by everyday life”. This particular collection of brief digestible articles, animations and videos covers: A frightening prospect (epidemiological statistics). How the disease affects your brain cells (an interactive … Continue reading →

Posted in Animal Studies, BBC News, In the News, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Aducanumab, Aducanumab (Biogen), Alzheimer’s Disease Clinical Trials, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-Beta Clearance in Mice, Amyloid-Related Imaging Abnormalities (ARIA), Amyloid-Related Imaging Abnormalities-Edema/Effusion (ARIA-E), Anti-Amyloid-β (Aβ) Immunotherapy Trials, BBC Health News, BBC iWonder Guide on Alzheimer's Disease, BBC iWonder Guides, Brain Drain: Brain Glymphatic Transport, Brain Glymphatic System, Clearance of Amyloid Beta Protein, CNS Lymphatic System: Hypothesis Regarding Poor Sleep Patterns and Neuropathology, Dementia Prevalence, Drug Side-Effects, Drug Trials, Glymphatic System, iWonder Guides (BBC), Lifestyle Risk Factors, Misfolded Proteins, Modifiable Risk Factors, Need For Sleep, Neurofibrillary Tangles, Neurofibrillary Tangles (NFTs), Neuronal Loss, Neuropathological Features, Neuropathology, Neuroprotective Lifestyles, Prevention, Prevention Agenda, Prevention Approaches, Prevention of Dementia, Preventive Health, Professor Maiken Nedergaard: University of Copenhagen, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Reasons for Termination of Trials, Sleep Duration, Sleep Hygiene, Sleep Patterns, Sleeping Well, Tau Tangles, Therapeutic-Induced ARIA, Treatment Side-Effects: Therapeutic-Induced ARIA, University of Copenhagen | Leave a comment

Alzheimer’s Disease: Solanezumab Drug Trial Flops (BBC News / Alzheimer’s and Dementia)

Posted on November 23, 2016 by Dementia and Elderly Care News

Summary The phase 3 EXPEDITION3 trial has been abandoned, as Solanezumab failed to slow cognitive decline in tests on around 2,000 patients with Alzheimer’s Disease. Several other amyloid-clearance drugs are going through trials apparently. Full Text Link Reference Walsh, F. … Continue reading →

Posted in BBC News, For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Alzheimer’s and Dementia (Journal), Alzheimer’s Disease Clinical Trials, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Avid Radiopharmaceuticals (Philadelphia), BBC Health News, Big Pharma, Clearance of Amyloid Beta Protein, Drug Trials, Drug Trials Failure Rate, Eli Lilly, Eli Lilly and Company (Indianapolis), EXPEDITION Studies, Intervention Trials, β-amyloid, LZAM, LZAN, Mild Alzheimer’s Disease, Misfolded Proteins, Neurofibrillary Tangles, Neuronal Loss, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Reasons for Termination of Trials, Solanezumab (Eli Lilly), Solanezumab EXPEDITION Trials, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody, United States, USA | Leave a comment

Acupuncture Appears Effective for Amnestic MCI? (NHS Choices / Acupuncture in Medicine)

Posted on August 7, 2016 by Dementia and Elderly Care News

Summary A recent systematic review examined carefully selected randomised controlled trials investigating the effectiveness and safety of acupuncture for treating mild cognitive impairment (MCI). The following NHS Choices Behind the Headlines critical appraisal places this research in context, but is … Continue reading →

New Hopes for Disease-Modifying Pharmacological Dementia Treatment (BBC News / AAIC / ARUK)

Posted on July 22, 2015 by Dementia and Elderly Care News

Summary Trials of the drug Solanezumab were abandoned in apparent failure in 2012. More detailed examination of the data has since revealed evidence that this medication may have a role in slowing the pace of progression in Alzheimer’s Disease slightly, … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer's Association International Conference (Washington, Alzheimer’s Association International Conference® (AAIC®) 2015, Alzheimer’s Research UK (ARUK), Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, ARUK: Alzheimer’s Research UK, BBC Health News, Big Pharma, Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies for Dementia, Dr Eric Karran: Director of Research at Alzheimer’s Research UK, Drug Development for Alzheimer's Disease, Drug-Development Pipeline, Eli Lilly, EXPEDITION Studies, β-amyloid, July 2015), Misfolded Proteins, Neurofibrillary Tangles, Neuronal Loss, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Solanezumab (Eli Lilly), Solanezumab EXPEDITION Trials, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody | Leave a comment

National Screening for Dementia Not Recommended (UK NSC / AHRQ / Annals of Internal Medicine / Epidemiology / International Journal of Epidemiology)

Posted on January 19, 2015 by Dementia and Elderly Care News

Summary The UK National Screening Committee (UK NSC) has upheld previous recommendations against screening people aged 65 and over for dementia. This decision follows an extensive review of the evidence. The UK NSC has concluded that tests for dementia, which … Continue reading →

Mild Cognitive Impairment: Diagnosis and Management (JAMA)

Posted on December 18, 2014 by Dementia and Elderly Care News

Summary Mild cognitive impairment (MCI), defined as the “pre-dementia stage on the continuum of cognitive decline, characterized by objective impairment in cognition that is not severe enough to require help with usual activities of daily living”, tends to occur in … Continue reading →

Posted in Community Care, For Nurses and Therapists (mostly), For Researchers (mostly), International, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, Systematic Reviews, Universal Interest | Tagged Aerobic Exercise, Cognitive Activity, Cognitive Decline, Department of Internal Medicine, Department of Neurology and Stroke Program: University of Michigan, Institute for Healthcare Policy and Innovation: University of Michigan, Institute for Social Research: University of Michigan, Institute of Gerontology: University of Michigan, JAMA, Late-Life Cognitive Decline, MCI, MCI: Mild Cognitive Impairment, Mental Wellbeing, Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), Mild Cognitive Impairment More Prevalent in Men, National Institute on Aging (NIA), Physical Activity, Physical Activity as a Protective Factor for Cognitive Decline and Dementia, Pre-Dementia (MCI), Primary Care, Progression of Mild Cognitive Impairment to Dementia, Rates of Conversion From Mild Cognitive Impairment to Dementia, Risk and Protective Factors for Cognitive Decline and Dementia, Social Engagement, Social Inclusion, United States, University of Michigan, USA, Veterans Affairs Center for Clinical Management Research: Michigan | Leave a comment

Concerning the Diagnostic Accuracy of Plasma and CSF Biomarkers (Cochrane Database)

Posted on August 2, 2014 by Dementia and Elderly Care News

Summary This systematic review investigates the diagnostic accuracy of blood plasma and CSF Aß levels for detecting patients with mild cognitive impairment (MCI) and who are likely to progress to Alzheimer’s Disease or other types of dementia. The accuracy of … Continue reading →

Posted in Charitable Bodies, Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Systematic Reviews, UK | Tagged Aß40, Aß42, ALOIS: the Cochrane Dementia and Cognitive Improvement Group, Alzheimer's Association, Alzheimer's Disease and Related Disorders Association (Now the Alzheimer's Association), Alzheimer’s Disease Biomarkers, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Apolipoprotein E, Asymptomatic Alzheimer’s Disease, Beta-Amyloid, Beta-Amyloid Plaques, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood-Based Biomarkers, Cambridge Institute of Public Health, Cambridge Institute of Public Health: Cambridge University, Candidate Blood Proteome Markers, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Cochrane Database, Cochrane Database of Systematic Reviews, Cochrane Dementia and Cognitive Improvement Group, Cochrane Register of Diagnostic Test Accuracy Studies, Cognitive Impairment, Cognitive Response to Progression of Pathophysiology, Conversion to Dementia From Prodromal Disease, CSF Aß Levels, CSF Aβ, CSF Biomarkers, CSF Tau, Dementia Screening, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV), Diagnostic Test Accuracy, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Differential Diagnosis, Early Screening, Fluid and Imaging Biomarkers, Imperial College London, Institute of Public Health: University of Cambridge, β-amyloid, β-Amyloid 1-42 (Aβ42), MCI: Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), National Institute of Neurological and Communicative Disorders and Stroke, Neurodegeneration, NINCDS-ADRDA Criteria, NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association, Plasma Biomarkers, Plasma Proteins, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Progression of Mild Cognitive Impairment to Dementia, Systematic Reviews and Meta-Analyses, Transition from Cognitive Impairment to Dementia, University of Birmingham, University of Cambridge, University of Oxford, University of Oxford: Radcliffe Department of Medicine, University of Western Australia, US Alzheimer's Association, Western Australian Centre for Health and Ageing (WACHA) | Leave a comment

Defeat Dementia Report (Alzheimer’s Research UK / OHE / BBC News)

Posted on June 23, 2014 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK (ARUK) released their “Defeat Dementia: the evidence and a vision for action” last week to coincide with the Global Dementia Legacy Event and the launch of their “Defeat Dementia” campaign. This report draws on analyses from … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Management of Condition, Models of Dementia Care, National, Non-Pharmacological Treatments, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Age of Dementia Onset, Alzheimer’s Disease: Prevalence, ARUK: Alzheimer’s Research UK, BBC Health News, Burden of Alzheimer’s Disease, Burden of Dementia, Burden on Caregivers, Carer Burden in Dementia, Defeat Dementia Campaign, Defeat Dementia Campaign (Alzheimer’s Research UK), Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies for Dementia, Economic Analyses, Economic Case for Prevention, Economic Modelling, Epidemiology, Epidemiology and Statistics, Family Carers, Global Dementia Legacy Event, Informal Carers, Institute for Public Policy Research (ippr), ippr: Institute for Public Policy Research, Office of Health Economics (OHE), Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Social Epidemiology, University College London, Unpaid Caregivers (Carers), Unpaid Carers, Wider Societal Burden | Leave a comment

Tag Archives: Progression of Mild Cognitive Impairment to Dementia

Brain Training Game May Improve Symptoms of Amnestic Mild Cognitive Impairment? (NHS Choices / International Journal of Neuropsychopharmacology)

Alzheimer’s Disease: Solanezumab Drug Trial Flops (BBC News / Alzheimer’s and Dementia)

Acupuncture Appears Effective for Amnestic MCI? (NHS Choices / Acupuncture in Medicine)

New Hopes for Disease-Modifying Pharmacological Dementia Treatment (BBC News / AAIC / ARUK)

National Screening for Dementia Not Recommended (UK NSC / AHRQ / Annals of Internal Medicine / Epidemiology / International Journal of Epidemiology)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites